Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of TST002 (Blosozumab) in Reduced Bone Mineral Density
NCT05391776Phase 1Unknown
- Sponsor
- Hangzhou Just Biotherapeutics
- Start
- Apr 2022
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in osteoporosis comparing TST002 with Placebo (2 arms). Primary endpoint: Adverse Events at 12 weeks. Status: unknown.
02
Drugs
blosozumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT05391776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05391776.